Luigi Montemurro, of Brigham and Women’s Hospital in Boston, met us at ERS 2019 in Madrid to discuss the recent trial of the fixed dose combination of atomoxetine and oxybutynin as the first successful pharmacotherapy for obstructive sleep apnoea.
Questions
1. Why is there not yet an effective pharmacotherapy for obstructive sleep apnoea (OSA)? (0:05)
2. What is the mechanism of action of the fixed dose combination of atomoxetine and oxybutynin (ato-oxy) in OSA? (1:16)
3. Could you tell us a little about the recent clinical trial of ato-oxy and its findings? (2:17)
4. What is the safety profile of this combination? (3:41)
5. What were the limitations of the study and what future studies are planned? (5:50)
Speaker disclosures: Luigi Taranto Montemurro is a consultant for Apnimed, Inc.
touchRESPIRATORY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Filmed at the European Respiratory Society (ERS) International Congress 2019, Madrid, Spain.
